Clinical Trial

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 30, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-11-19; most recent amendment 2025-12-22.
Status change: Recruiting → Active, Not Recruiting 2023-04-23
Status change: Not Yet Recruiting → Recruiting 2021-08-16
Trial Details
NCT Number NCT04639180
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Hepatocellular Carcinoma (HCC)
Enrollment 687 participants
Start Date 2021-04-01
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-30